Corcept Therapeutics Inc. vs. Eli Lilly & Co.
Eli Lilly & Co. (LLY) comes out ahead, leading on 8 of 9 compared factors.
Size & Scale
| CORT | LLY | |
|---|---|---|
| Market Cap | $12.55 billion | $1.05 trillion |
| Revenue (TTM) | $741.17 million | $79.67 billion |
| Net Income (TTM) | $106.11 million | $26.71 billion |
LLY leads on 3 of 3 size & scale factors.
Valuation
| CORT | LLY | |
|---|---|---|
| P/E Ratio | 133.45 | 39.77 |
| Price / Book | 19.86 | 31.14 |
| Price / Sales | 16.93 | 13.24 |
LLY leads on 2 of 3 valuation factors.
Profitability
| CORT | LLY | |
|---|---|---|
| Net Margin | 14.32% | 33.53% |
| Return on Equity | 16.79% | 78.84% |
LLY leads on 2 of 2 profitability factors.
Dividend
| CORT | LLY | |
|---|---|---|
| Dividend Yield | — | 0.58% |
| Payout Ratio | — | 23.23 |
CORT and LLY split the dividend factors evenly.
Risk & Sentiment
| CORT | LLY | |
|---|---|---|
| Short Interest | 16.06% | 1.29% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: CORT overview, CORT financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.
